11th February 2016

TMT

Soitec Price EUR0.50

				SOI FP	
Bloomberg	Bloomberg				
Reuters					
	12-month High / Low (EUR)				
• •	Market Cap (EURm)				
	Ev (BG Estimates) (EURm)				
	Avg. 6m daily volume (000)				
3y EPS CAGR	3y EPS CAGR				
	1 M	3 M	6 M 33	l/12/15	
Absolute perf.	-21.9%	-34.2%	-26.5%	-21.9%	
Semiconductors	-5.2%	-17.6%	-16.4%	-15.8%	
DJ Stoxx 600	-7.7%	-16.2%	-21.2%	-13.8%	
YEnd Mar. (EURm)	03/ 15	03/ 16e	03/ 17e	03/ 18e	
Sales	222.9	235.9	271.4	298.6	
% change		5.9%	15.1%	10.0%	
EBITDA	-67.9	43.3	56.8	71.3	
EBIT	-125.9	6.3	11.6	22.4	
% change		NS	82.3%	93.2%	
Net income	-107.8	-25.1	4.4	14.5	
% change		76.7%	NS	NM	
	03/ 15	03/ 16e	03/ 17e	03/ 18e	
Operating margin	NM	2.7	4.3	7.5	
Net margin	NM	NM	1.4	4.9	
ROE	-516.1	-102.9	6.5	17.6	
ROCE	-63.0	4.2	8.8	19.7	
Gearing	300.4	NM	NM	34.1	
(EUR)	03/ 15	03/ 16e	03/17e	03/ 18e	
EPS	-0.51	-0.08	0.01	0.04	
% change	-	84.5%	NS	NM	
P/E	NS	NS	44.2x	13.3x	
FCF yield (%)	NM	NM	13.3%	18.4%	
Dividends (EUR)	0.00	0.00	0.00	0.00	
Div yield (%)	NM	NM	NM	NM	
EV/Sales	1.2x	0.9x	0.7x	0.5x	
EV/EBITDA	NS	4.7x	3.2x	2.0x	
EV/EBIT	NS	32.3x	15.5x	6.4x	



Finally, there will be two successive capital increases

Fair Value EUR0.65 vs. EUR0.8 (+30%)

NEUTRAL

Yesterday, Soitec announced that it is preparing two successive capital increases for a total amount in the range of EUR130-180m. First, the group is proposing a reserved capital increase of EUR76.5m for BPI France, CEA and a Chinese investment fund, National Silicon Industry Group. This reserved capital increase will go ahead at EUR0.55 per share (vs. current share price of EUR0.50), which is relutive regarding the current share price but dilutive for our FV. Then, a second capital increase with preferential subscription rights is to be proposed for a total amount to be determined in the range of EUR53.5-103.5m. The amount will depend on potential 2018 OCEANE buy-back opportunities. Proceeds from the operations will be used to repay the 2018 OCEANE and accelerate investments to develop Soitec's FD-SOI production capacities. We update our model to include the impact of the reserved capital increase only (see below). Our new FV is EUR0.65

ANALYSIS

- Yesterday, Soitec announced that it is preparing two successive capital increases. In a press . release published yesterday, the group announced that it intends to carry out two capital increases for a total amount in the range of EUR130m to EUR180m. First, a reserved capital increase of EUR76.5m for BPI France, CEA and a Chinese investment fund National Silicon Industry Group. At the closing of this operation, all of these investors will hold about 14.5% of Soitec shares. This reserved capital increase will be at a price of EUR0.55 per share (vs. current share price of EUR0.50), triggering the issuance of about 139m shares, representing 55% of the current number of outstanding shares and having an impact of 40% on our FV (taking into account the 20% impact we already included in our previous FV). We believe the timing of this operation will be late March, early April 2016. In addition to that, the group is preparing a second capital increase with preferential subscription rights for a total amount to be determined in the range of EUR53.5m to EUR103.5m. At the top end of the range and at the current share price of EUR0.50, the group would issue about 200m shares, or 52% of outstanding shares after the reserved capital increase. We also note that the proposed amount will depend on potential 2018 OCEANE buy-back opportunities. This second capital increase should take place between March and June 2016 in our view.
- Proceeds from the operations will be used to pay down debt and accelerate investments to develop Soitec's FD-SOI production capacities. At the end of 2015, the group had a gross debt position of EUR220m of which about EUR42m in bridging loans issued in May 2015 to be reimbursed before May 2016. In addition, we recall that the gross cash position was EUR51m at this time. The 2018 OCEANE represents debt of about EUR100m to be repaid before September 2018. Finally, a second part of the proceeds will be used for investments in production tools and especially FD-SOI production. We believe the group aims to develop capacities of over 400K wafers per years, which would require investments of about EUR40m for strengthening current production tools (new cleaning tools, new metrology tools...).

VALUATION

- We have updated our model. Given the advanced talks with quoted investors CEAI, BPI France and the Chinese investment fund National Silicon Industry Group, we have included all the impacts of the reserved capital increase in our FV. We remind that our previous FV of EUR0.8 included a dilution of 20% due to the capital increase already expected. However, the second capital increase remains uncertain so far, as a result, we do not include any impact for this one. Our new FV is EUR0.65. Other things being equal, including the impact of the second capital increase (at current share price and for an amount of EUR103.5m) our FV would be EUR0.5.
- Soitec shares trade at a 2016e EV/Sales ratio of 0.9x and 2016e EV/EBIT ratio of 16.3x.

NEXT CATALYSTS

During April: Q4 2016e sales.



Analyst : Dorian Terral 33(0) 1.56.68.75.92 dterral@bryangarnier.com Sector Team : Richard-Maxime Beaudoux Thomas Coudry Gregory Ramirez

BRYAN, GARNIER & CO

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a
DUT	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 61.9%

NEUTRAL ratings 29.1%

SELL ratings 9%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	eholding Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	
2	Issuer shareholding in Bryan Garnier	olding in Bryan The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	
5	Lead/co-lead manager	ager In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.		No
7	Research agreement A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.		No
8	Analyst receipt or purchase of shares in Issuer		
9	Remuneration of analyst	lyst The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	
10	Corporate finance client	orate finance client In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	
11	Analyst has short position The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.		No
12	Analyst has long position The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.		No
13	Bryan Garnier executive is an officer		
14	Analyst disclosure The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.		Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

BRYAN, GARNIER & CO

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudential et de		FINMA	
(FCA)	resolution (ACPR)			

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm or an associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever. Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..

BRYAN, GARNIER & CO